Novel theophylline oral drops for pediatric use and biological evaluation

Area of Science:

• Pharmacology
• Pediatric Medicine
• Respiratory Diseases

Background:

• Asthma significantly impacts children's quality of life globally.
• Theophylline, a phosphodiesterase inhibitor, is used for respiratory diseases but lacks a pediatric formulation.
• Existing treatments do not cater to the specific needs of pediatric asthma management.

Purpose of the Study:

• To develop and pharmacologically evaluate a novel oral theophylline formulation for pediatric use.
• To investigate the protective effects of this theophylline formulation on airway inflammation and oxidative stress in a mouse asthma model.
• To assess the formulation's stability, pharmacokinetics, and therapeutic potential in managing childhood asthma.

Main Methods:

• Development and characterization of an oral theophylline formulation (dose, rheology, pH, stability, pharmacokinetics).
• Evaluation in an ovalbumin-induced asthma model in Balb/c mice.
• Assessment of mucus production, inflammatory markers, reactive oxygen species generation, and lung histology.

Main Results:

• The theophylline formulation met all quality and pharmacokinetic specifications.
• Theophylline significantly inhibited ovalbumin-induced mucus production and airway inflammation.
• The formulation reduced reactive oxygen species generation and mitigated lung cell damage in the asthma model.

Conclusions:

• The novel oral theophylline formulation is stable, well-characterized, and effective in preclinical asthma models.
• Theophylline demonstrates potential in relieving asthmatic airway inflammation and oxidative stress in children.
• This formulation represents a promising therapeutic option for managing childhood asthma.